EUVIMEDEUVIMED entdecken
Crossref

Dupilumab-Associated Ocular Surface Disease in Patients with Atopic Dermatitis Is Frequent: A Nationwide Real-World Evidence Study

Ane Marie Hovmand Nøhr, Pernille May Hansen, Michael Møller-Hansen, Henrik Hedegaard Pliess Larsen, Amalie Thorsti Møller Rønnstad, Simon Francis Thomsen, Claus Otto Carl Zachariae, Kristina Ibler, Charlotte G Mortz, Carsten Bindslev-Jensen, Mette Sondergaard Deleuran, Christian Vestergaard und 3 weitere

Dermatology · 13.09.2025 · 1-10

DOI: 10.1159/000548467 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatology, online erschienen am 13.09.2025. Verfasst von Ane Marie Hovmand Nøhr und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

New biologic treatments are increasingly used for the treatment of moderate-to-severe atopic dermatitis (AD). This study examined clinical characteristics of patients with Dupilumab-associated ocular surface disease (DAOSD).

Methods

A total of 382 patients were included in a retrospective nationwide cohort study of all Danish adults treated with Dupilumab for AD for more than 16 weeks.

Results

The frequency of DAOSD was 37.7% with a median follow-up of 1.6 years. Before initiating treatment, 61.3% of the DAOSD patients already had preexisting ocular surface disease (OSD), why the DAOSD group was then subdivided in two groups: one with preexisting OSD and one without preexisting OSD. Patients who developed DAOSD had a longer median duration of AD (41.5 and 44 for patients with preexisting OSD and patients without preexisting OSD) vs. 33 years (non-DAOSD), p = 0.005, a higher median reduction in EASI score (93.3% and 90.2% vs. 83.8%, p = 0.006) and more frequently rhinitis (49.4% and 52.7% vs. 37.1%, p = 0.031). In 75% of cases, DAOSD presented before week nine, conjunctivitis was the most common sign of DAOSD (73.2%) and to treat DAOSD, ophthalmologists prescribed lubricating eye drops to patients with preexisting OSD and patients without preexisting OSD drops in 88.5% and 87.3 of the cases, and mild (e.g., hydrocortisone) and strong (e.g., dexamethasone) corticosteroid eye drops equally frequent (24.1 and 25.3% vs. 16.4% and 29.1%). In 5% of the cohort, Dupilumab treatment was discontinued due to DAOSD (n = 19), even though these patients received lubricating eye drops (84%), mild steroids (41.1), and strong steroids (31.6%).

Conclusion

DAOSD should be recognized by dermatologists and should lead to consideration of early referral to ophthalmologists.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAntibodies, Monoclonal, HumanizedHumansMaleFemaleRetrospective StudiesAdultMiddle AgedDenmarkAgedConjunctivitis

Stichwörter der Autor:innen

Atopic dermatitisConjunctivitisDupilumabOcular surface diseaseRhinitis

Substanzen

dupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Ophthalmology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
  • Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Research Unit for General Practice and Section of General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
  • Department of Dermatology, Copenhagen University Hospital - Bispebjerg, Copenhagen, Denmark.
  • Department of Dermatology and Allergy, Copenhagen University Hospital - Gentofte, Gentofte, Denmark.

Zitieren

APA

Nøhr, A. M. H., Hansen, P. M., Møller-Hansen, M., Larsen, H. H. P., Rønnstad, A. T. M., Thomsen, S. F., Zachariae, C. O. C., Ibler, K., Mortz, C. G., Bindslev-Jensen, C., Deleuran, M. S., Vestergaard, C., Bjerring, P., Thyssen, J. P., & Heegaard, S. (2025). Dupilumab-Associated Ocular Surface Disease in Patients with Atopic Dermatitis Is Frequent: A Nationwide Real-World Evidence Study. Dermatology, 1-10. https://doi.org/10.1159/000548467

Vancouver

Nøhr AMH, Hansen PM, Møller-Hansen M, Larsen HHP, Rønnstad ATM, Thomsen SF, et al. Dupilumab-Associated Ocular Surface Disease in Patients with Atopic Dermatitis Is Frequent: A Nationwide Real-World Evidence Study. Dermatology. 2025:1-10. doi:10.1159/000548467

BibTeX
@article{Nhr2025,
  author = {Nøhr, Ane Marie Hovmand and Hansen, Pernille May and Møller-Hansen, Michael and Larsen, Henrik Hedegaard Pliess and Rønnstad, Amalie Thorsti Møller and Thomsen, Simon Francis and Zachariae, Claus Otto Carl and Ibler, Kristina and Mortz, Charlotte G and Bindslev-Jensen, Carsten and Deleuran, Mette Sondergaard and Vestergaard, Christian and Bjerring, Peter and Thyssen, Jacob P and Heegaard, Steffen},
  title = {Dupilumab-Associated Ocular Surface Disease in Patients with Atopic Dermatitis Is Frequent: A Nationwide Real-World Evidence Study},
  journal = {Dermatology},
  year = {2025},
  pages = {1--10},
  doi = {10.1159/000548467}
}
Kostenlos starten →